Publications by authors named "Juanhua He"
Article Synopsis
- Two sarbecoviruses, SARS-CoV and SARS-CoV-2, pose significant public health challenges due to their interaction with the ACE2 receptor, with some showing deletions in their receptor-binding domain (RBD).
- This study focused on two related sarbecoviruses, BtKY72 and BM48-31, finding that BtKY72 had a broader range for ACE2 binding, which is critical for understanding virus-host interactions.
- By analyzing the structure of BtKY72 bound to bat ACE2 and identifying key residues, the study also revealed how mutations in the RBD could enable binding to human ACE2, paving the way for potential treatments against emerging sarbecoviruses.
Article Synopsis
- * Researchers identified two dominant HPV-E7 specific TCRs from HLA-A11:01 transgenic mice through advanced sorting and sequencing methods, which showed specific interactions with E7 proteins.
- * The engineered TCR-T cells demonstrated significant responsiveness and multifunctional cytokine production, suggesting they are promising candidates for future treatments aimed at HPV-E7 in tumor immunotherapy.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted between humans and minks, and some mutations in the spike (S) protein, especially in the receptor-binding domain (RBD), have been identified in mink-derived viruses. Here, we examined binding of the mink angiotensin-converting enzyme 2 (ACE2) receptor to mink-derived and important human-originating variants, and we demonstrated that most of the RBD variants increased the binding affinities to mink ACE2 (mkACE2). Cryo-electron microscopy structures of the mkACE2-RBD Y453F (with a Y-to-F change at position 453) and mkACE2-RBD F486L complexes helped identify the key residues that facilitate changes in mkACE2 binding affinity.
View Article and Find Full Text PDFImmune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors. Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma. Here, we report the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab.
View Article and Find Full Text PDF